Cargando…

Neuropeptide modulation of lymphatic smooth muscle tone in the canine forelimb

Neurokinin A and B are putative inflammatory mediators. We assessed their ability to alter prenodal lymphatic resistance. Intralymphatic neurokinin A (3.0 × 10(−6), 3.0 × 10(−5) and 3.0 × 10(−4) mol l(−1)) significantly constricted lymphatics at the two highest doses. Preliminary experiments suggest...

Descripción completa

Detalles Bibliográficos
Autor principal: Dobbins, David E.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 1992
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2365347/
https://www.ncbi.nlm.nih.gov/pubmed/18475467
http://dx.doi.org/10.1155/S096293519200036X
Descripción
Sumario:Neurokinin A and B are putative inflammatory mediators. We assessed their ability to alter prenodal lymphatic resistance. Intralymphatic neurokinin A (3.0 × 10(−6), 3.0 × 10(−5) and 3.0 × 10(−4) mol l(−1)) significantly constricted lymphatics at the two highest doses. Preliminary experiments suggested that neurokinin B might dilate lymphatics. To test this, lymphatic pressure was increased by norepinephrine (3.1 × 10(−6) mol l(−1)). Neurokinin B (2.7 × 10(−4) mol l(−1)) was then infused intralymphatically during norepinephrine infusion. Norepinephrine increased perfusion pressure from 5.6 ± 0.6 mmHg to 12.1 ± 1.4 mmHg. Subsequent infusion of neurokinin B significantly decreased lymphatic perfusion pressure from 11.9 ± 1.3 mmHg to 9.9 ± 1.1 mmHg. These data indicate that neurokinin A and B can alter lymphatic resistance and are consistent with the hypothesis that lymph vessel function may be subject to modulation by neurokinins.